LYEL
Lyell Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.37
+0.35%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
Market Cap
$352.14M
MomentumView details →
1D Return
+0.35%
YTD Return
−53.74%
RSI (14)
48.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
Market Cap
$352.14M
RSI (14)
48.2
MomentumView details →
1D Return
+0.35%
YTD Return
−53.74%
SummaryUpdated Jun 1, 2026
Lyell Immunopharma, Inc. (NASDAQ:LYEL) is a clinical-stage biotechnology company founded in 2018 and headquartered in South San Francisco, California. The company went public in June 2021 and specializes in developing novel T cell therapies for patients with solid tumors. Lyell focuses on overcoming the limitations of current cancer immunotherapies by reprogramming T cells to maintain their effectiveness against cancer over extended periods, addressing a critical challenge in oncology where T cells often become exhausted and lose their cancer-fighting capabilities.
Similar companies
Latest newsMore news →
Lyell Immunopharma reported its Q2 2026 financial results, with revenue of $4,000, a GAAP net loss of $44.8 million, and cash and marketable securities of $228.0 million as of June 30, 2026.30d agoAbCellera Biologics Inc. appointed Lynn Seely, M.D. as a Class III director, effective June 30, 2026.61d ago